Enarodustat (formerly JTZ-951; JTZ951; Enaroy) is an orally bioactive hypoxia inducible factor-proly hydroxylase (HIF-PH) inhibitor approved (in 2020) in Japan for the treatment of anemia associated with chronic kidney disease (CKD). It inhibits HIF-PH with an EC50 of 0.22 μM. As an anti-anaemic drug, Enarodustat acts by stabilizing HIF-α protein and inducing erythropoiesis without effects on the function of vascular endothelial growth factor. Enarodustat increases endogenous erythropoietin levels in the treatment of anemia associated with chronic kidney disease (CKD). JTZ-951 induces erythropoiesis without affecting VEGF function. JTZ-951 may be a new oral candidate that increases and maintains hemoglobin concentrations in renal anemia patients.

纯度：≥98%

CAS：1262132-81-9